The overall aim of the research of the CPH-DIRECT is to advance in a decisive way how we predict, evaluate and prevent the onset and progression of type 1 diabetes (T1D).
This will be achieved by creating novel tools, such as biomarkers, disease models and clinical trial paradigms. These tools will allow us to distinguish and understand at the cellular and molecular level distinctive paths of ontogeny and progression in this heterogeneous disease, thus impacting on the future management of T1D patients and at risk individuals.
Risk for and development of type 1 diabetes
Improving metabolic outcome of type 1 diabetes treatment